Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 140

1.

Evaluation of SERS labeling of CD20 on CLL cells using optical microscopy and fluorescence flow cytometry.

MacLaughlin CM, Parker EP, Walker GC, Wang C.

Nanomedicine. 2013 Jan;9(1):55-64. doi: 10.1016/j.nano.2012.04.003. Epub 2012 Apr 26.

PMID:
22542823
2.

Surface-enhanced Raman scattering dye-labeled Au nanoparticles for triplexed detection of leukemia and lymphoma cells and SERS flow cytometry.

MacLaughlin CM, Mullaithilaga N, Yang G, Ip SY, Wang C, Walker GC.

Langmuir. 2013 Feb 12;29(6):1908-19. doi: 10.1021/la303931c. Epub 2013 Jan 29.

PMID:
23360230
3.

Single cell analysis using surface enhanced Raman scattering (SERS) tags.

Nolan JP, Duggan E, Liu E, Condello D, Dave I, Stoner SA.

Methods. 2012 Jul;57(3):272-9. doi: 10.1016/j.ymeth.2012.03.024. Epub 2012 Apr 4. Review.

4.

Detection of chronic lymphocytic leukemia cell surface markers using surface enhanced Raman scattering gold nanoparticles.

Nguyen CT, Nguyen JT, Rutledge S, Zhang J, Wang C, Walker GC.

Cancer Lett. 2010 Jun 1;292(1):91-7. doi: 10.1016/j.canlet.2009.11.011. Epub 2009 Dec 29.

PMID:
20042272
5.
6.

Selection of B-cell chronic lymphocytic leukemia cell variants by therapy with anti-CD20 monoclonal antibody rituximab.

Pickartz T, Ringel F, Wedde M, Renz H, Klein A, von Neuhoff N, Dreger P, Kreuzer KA, Schmidt CA, Srock S, Schoeler D, Schriever F.

Exp Hematol. 2001 Dec;29(12):1410-6.

PMID:
11750099
7.

Pan B-cell markers are not redundant in analysis of chronic lymphocytic leukemia (CLL).

Monaghan SA, Peterson LC, James C, Marszalek L, Khoong A, Bachta DJ, Karpus WJ, Goolsby CL.

Cytometry B Clin Cytom. 2003 Nov;56(1):30-42.

8.

CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59.

Golay J, Lazzari M, Facchinetti V, Bernasconi S, Borleri G, Barbui T, Rambaldi A, Introna M.

Blood. 2001 Dec 1;98(12):3383-9.

10.

Gold nanoparticle-paper as a three-dimensional surface enhanced Raman scattering substrate.

Ngo YH, Li D, Simon GP, Garnier G.

Langmuir. 2012 Jun 12;28(23):8782-90. doi: 10.1021/la3012734. Epub 2012 Jun 1.

PMID:
22594710
11.

Transient down-modulation of CD20 by rituximab in patients with chronic lymphocytic leukemia.

Jilani I, O'Brien S, Manshuri T, Thomas DA, Thomazy VA, Imam M, Naeem S, Verstovsek S, Kantarjian H, Giles F, Keating M, Albitar M.

Blood. 2003 Nov 15;102(10):3514-20. Epub 2003 Jul 31.

12.

[Distribution and force spectroscopy of CD20 antigen-antibody binding on the B cell surface].

Wang Q, Lu Y, Li S, Wang M, Cai J.

Sheng Wu Gong Cheng Xue Bao. 2011 Jan;27(1):131-6. Chinese.

PMID:
21553499
14.

Rational design of Raman-labeled nanoparticles for a dual-modality, light scattering immunoassay on a polystyrene substrate.

Israelsen ND, Wooley D, Hanson C, Vargis E.

J Biol Eng. 2016 Jan 7;10:2. doi: 10.1186/s13036-015-0023-y. eCollection 2016.

15.

Rituximab infusion promotes rapid complement depletion and acute CD20 loss in chronic lymphocytic leukemia.

Kennedy AD, Beum PV, Solga MD, DiLillo DJ, Lindorfer MA, Hess CE, Densmore JJ, Williams ME, Taylor RP.

J Immunol. 2004 Mar 1;172(5):3280-8.

17.

Detection of inflammation in vivo by surface-enhanced Raman scattering provides higher sensitivity than conventional fluorescence imaging.

McQueenie R, Stevenson R, Benson R, MacRitchie N, McInnes I, Maffia P, Faulds K, Graham D, Brewer J, Garside P.

Anal Chem. 2012 Jul 17;84(14):5968-75. doi: 10.1021/ac3006445. Epub 2012 Jul 3.

PMID:
22816780
18.

Comparison of fluorescein and phycoerythrin conjugates for quantifying CD20 expression on normal and leukemic B-cells.

Wang L, Abbasi F, Gaigalas AK, Vogt RF, Marti GE.

Cytometry B Clin Cytom. 2006 Nov 15;70(6):410-5.

19.

Reduced expression of CD20 antigen as a characteristic marker for chronic lymphocytic leukemia.

Almasri NM, Duque RE, Iturraspe J, Everett E, Braylan RC.

Am J Hematol. 1992 Aug;40(4):259-63.

PMID:
1380203
20.

Heterogeneity and clinical relevance of the intensity of CD20 and immunoglobulin light-chain expression in B-cell chronic lymphocytic leukemia.

Tefferi A, Bartholmai BJ, Witzig TE, Li CY, Hanson CA, Phyliky RL.

Am J Clin Pathol. 1996 Oct;106(4):457-61.

Items per page

Supplemental Content

Write to the Help Desk